Billiontoone (NASDAQ:BLLN) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Billiontoone (NASDAQ:BLLN) from a buy rating to a hold rating in a research note released on Saturday.

Several other research firms also recently weighed in on BLLN. Guggenheim initiated coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. BTIG Research decreased their price target on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, August 6th. JPMorgan Chase & Co. lowered their price objective on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research note on Thursday, August 6th. Finally, Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Billiontoone presently has a consensus rating of “Moderate Buy” and an average target price of $126.71.

Billiontoone Price Performance

Shares of NASDAQ BLLN opened at $98.65 on Friday. Billiontoone has a fifty-two week low of $61.96 and a fifty-two week high of $150.44. The company has a market cap of $4.54 billion and a PE ratio of 140.93. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69. The business has a 50-day simple moving average of $116.65 and a two-hundred day simple moving average of $94.40.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. The firm had revenue of $109.45 million for the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. As a group, equities analysts expect that Billiontoone will post 0.92 EPS for the current fiscal year.

Insider Buying and Selling at Billiontoone

In other Billiontoone news, insider Nancy Joann Johnson sold 801 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $124.91, for a total transaction of $100,052.91. Following the sale, the insider directly owned 21,099 shares of the company’s stock, valued at approximately $2,635,476.09. This trade represents a 3.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Oguzhan Atay sold 32,500 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $136.95, for a total value of $4,450,875.00. Following the sale, the chief executive officer directly owned 20,000 shares in the company, valued at $2,739,000. This represents a 61.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 202,049 shares of company stock worth $23,496,861 over the last ninety days. 50.22% of the stock is owned by insiders.

Institutional Trading of Billiontoone

A number of hedge funds have recently modified their holdings of the stock. Massachusetts Financial Services Co. MA acquired a new stake in Billiontoone during the fourth quarter worth about $13,373,000. Baillie Gifford & Co. purchased a new position in Billiontoone in the fourth quarter valued at $103,786,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Billiontoone in the fourth quarter valued at $1,348,000. UBS Group AG acquired a new position in shares of Billiontoone in the fourth quarter worth about $2,586,000. Finally, Renaissance Capital LLC acquired a new position in shares of Billiontoone in the fourth quarter worth about $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.